GPhA Warns FDA On ANDA Review Transparency
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee negotiations could be 'lengthy and very detailed' unless FDA does 'the right thing' and implements 'effective' communication practices, generic trade group says.